CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Last trade$78.95
Day change-$5.83 (-6.88%)
Day range$73.13 – $86.06
Volume2,153,344
Market cap$7.57B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$7.57B
Price / earnings
—
Price / book
7.64×
Price / sales
1,228.1×
EV / sales
1,224×
EV / EBITDA
-28.91×
Profitability
Earnings per share
-$2.66
Return on assets
-22.69%
Return on equity
-23.96%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
21.7×
Quick ratio
21.68×
Cash ratio
0.61×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$189.17M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CGON, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$1.6M
$1.16M
$1.08M
$2.32M
$1.67M
$0
$52K
$456K
Cost of revenue
$2.67M
$3.93M
$2.96M
$3.07M
$1.58M
$0
$0
$0
Gross profit
-$1.07M
-$2.77M
-$1.88M
-$748K
$89K
$0
$52K
$456K
Selling, general and administrative
$22.96M
$28.98M
$20.78M
$17.99M
$23.33M
$17.41M
$14.79M
$11.71M
Research and development
$39.22M
$54.66M
$43.73M
$29.96M
$27.88M
$31.33M
$27.47M
$26.8M
Total operating expenses
$62.18M
$83.63M
$64.51M
$47.95M
$51.22M
$48.74M
$42.26M
$38.51M
Operating income
-$63.25M
-$86.4M
-$66.39M
-$48.7M
-$51.13M
-$48.74M
-$42.2M
-$38.05M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$56.89M
-$79.06M
-$60.2M
-$41.31M
-$43.81M
-$41.43M
-$34.45M
-$31.8M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$56.89M
-$79.06M
-$60.2M
-$41.31M
-$43.81M
-$41.43M
-$34.45M
-$31.8M
Net income attributable to common shareholders
-$56.89M
-$79.06M
-$60.2M
-$41.31M
-$43.81M
-$41.43M
-$34.45M
-$31.8M
EBITDA
-$62.09M
-$85.55M
-$65.55M
-$47.85M
-$50.71M
-$48.59M
-$42.18M
-$38.05M
Basic earnings per share
-$0.64
-$0.90
-$0.71
-$0.52
-$0.57
-$0.54
-$0.45
-$0.46
Diluted earnings per share
-$0.64
-$0.90
-$0.71
-$0.52
-$0.57
-$0.54
-$0.45
-$0.46
Recent news
Company coverage with links to the original publishers.
CG Oncology (CGON) reported a quarterly loss of $0.64 per share, beating consensus estimates of $0.86 loss, representing a 25.58% earnings surprise. Revenue of $1.6 million surpassed estimates by 48.52%, though down slightly year-over-year. The stock has gained 56.1% year-to-date, significantly outperforming the S&P 500's 7.4% gain. However, the company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
The ALPS Medical Breakthroughs ETF (SBIO) is a passively managed healthcare ETF that tracks small-cap and mid-cap pharmaceutical and biotechnology stocks in Phase II or Phase III FDA clinical trials. With a 0.5% expense ratio, $243.54 million in assets, and 107 holdings, it has delivered 32.1% year-to-date returns and 82.83% over 12 months. However, it carries high risk with a beta of 0.74 and 30.54% standard deviation. The fund received a Zacks ETF Rank of 3 (Hold), with alternatives like VHT and XLV offering lower expense ratios.
CG Oncology announced that its CEO Arthur Kuan will participate in fireside chat presentations at the Cantor Fitzgerald Global Healthcare Conference on September 9, 2026, and the Morgan Stanley Global Healthcare Conference on September 14, 2026. The company is a late-stage clinical biopharmaceutical firm developing immunotherapies for bladder cancer treatment.
Kuehn Law is investigating whether officers and directors of CG Oncology, Inc. breached fiduciary duties to shareholders through potential self-dealing. Long-term shareholders may be entitled to damages and corporate governance reforms. The law firm is seeking shareholders to participate in the investigation at no cost.
CG Oncology announced publication of Phase 3 BOND-003 Cohort C trial results for cretostimogene grenadenorepvec in treating high-risk, BCG-unresponsive non-muscle invasive bladder cancer. The study demonstrated 75.5% complete response rates, median duration of response of 27.9 months, 89% bladder preservation at 12 months, and a favorable safety profile with no Grade 3+ adverse events.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.